135 related articles for article (PubMed ID: 23002332)
1. Post-endoscopic retrograde cholangio-pancreatography pancreatitis: is time for a new preventive approach?
Tammaro S; Caruso R; Pallone F; Monteleone G
World J Gastroenterol; 2012 Sep; 18(34):4635-8. PubMed ID: 23002332
[TBL] [Abstract][Full Text] [Related]
2. Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients.
Levenick JM; Gordon SR; Fadden LL; Levy LC; Rockacy MJ; Hyder SM; Lacy BE; Bensen SP; Parr DD; Gardner TB
Gastroenterology; 2016 Apr; 150(4):911-7; quiz e19. PubMed ID: 26775631
[TBL] [Abstract][Full Text] [Related]
3. Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial.
Qian YY; Chen H; Tang XY; Jiang X; Qian W; Zou WB; Xin L; Li B; Qi YF; Hu LH; Zou DW; Jin ZD; Wang D; Du YQ; Wang LW; Liu F; Li ZS; Liao Z
Trials; 2017 Nov; 18(1):513. PubMed ID: 29096689
[TBL] [Abstract][Full Text] [Related]
4. Effect of rectal indomethacin on the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography for choledocholithiasis: a prospective randomized clinical trial.
Liu KJ; Hu Y; Guo SB
Rev Esp Enferm Dig; 2024 Apr; 116(4):20-208. PubMed ID: 37982566
[TBL] [Abstract][Full Text] [Related]
5. Prevention of post-ERCP complications.
Triki L; Tringali A; Arvanitakis M; Schepis T
Best Pract Res Clin Gastroenterol; 2024 Mar; 69():101906. PubMed ID: 38749582
[TBL] [Abstract][Full Text] [Related]
6. Intravenous Hemin, a potential heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in humans: Results of a randomized multicentric multinational placebo-controlled trial.
Yared RA; Chen CC; Vandorpe A; Arvanitakis M; Delhaye M; Viesca MFY; Huberty V; Blero D; Toussaint E; Hittelet A; Verset D; Margos W; Le Moine O; Njimi H; Liao WC; Devière J; Lemmers A
Pancreatology; 2024 May; 24(3):363-369. PubMed ID: 38431445
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drugs before endoscopic ultrasound guided tissue acquisition to reduce the incidence of post procedural pancreatitis.
de Jong M; van Delft F; Roozen C; van Geenen EJ; Bisseling T; Siersema P; Bruno M
World J Gastroenterol; 2024 Feb; 30(8):811-816. PubMed ID: 38516233
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the pharmacological therapy to prevent post ERCP acute pancreatitis: a network meta-analysis.
Rojas-Victoria EJ; Hernández-Ruiz SI; García-Perdomo HA
Expert Rev Gastroenterol Hepatol; 2024; 18(4-5):203-215. PubMed ID: 38725175
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial.
Shah TU; Liddle R; Branch MS; Jowell P; Obando J; Poleski M
JOP; 2012 Sep; 13(5):514-8. PubMed ID: 22964958
[TBL] [Abstract][Full Text] [Related]
10. Does indomethacin reduce the risk of thromboembolic events in patients undergoing ERCP?
Wu J; Ding H; Mei Q
Gastrointest Endosc; 2024 May; 99(5):862. PubMed ID: 38649226
[No Abstract] [Full Text] [Related]
11. Pancreatic steatosis: Identification of yet another "new" modifiable high-risk factor for post-ERCP pancreatitis?
Weston BR
Gastrointest Endosc; 2024 Feb; 99(2):224-226. PubMed ID: 38237965
[No Abstract] [Full Text] [Related]
12. Update in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Gellért B; Patai ÁV; Hritz I
Ann Gastroenterol; 2024; 37(3):266-279. PubMed ID: 38779635
[TBL] [Abstract][Full Text] [Related]
13. Targeting inflammation to prevent severe acute pancreatitis: NSAIDs are not the holy grail.
Capurso G; Malesci A
Dig Liver Dis; 2024 Jun; 56(6):1021-1022. PubMed ID: 38462428
[No Abstract] [Full Text] [Related]
14. Preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: what can be done?
Hauser G; Milosevic M; Stimac D; Zerem E; Jovanović P; Blazevic I
World J Gastroenterol; 2015 Jan; 21(4):1069-80. PubMed ID: 25632179
[TBL] [Abstract][Full Text] [Related]
15. Post-endoscopic retrograde cholangiopancreatography pancreatitis.
Thaker AM; Mosko JD; Berzin TM
Gastroenterol Rep (Oxf); 2015 Feb; 3(1):32-40. PubMed ID: 25406464
[TBL] [Abstract][Full Text] [Related]
16. The effect of indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis.
Ahmad D; Lopez KT; Esmadi MA; Oroszi G; Matteson-Kome ML; Choudhary A; Bechtold ML
Pancreas; 2014 Apr; 43(3):338-42. PubMed ID: 24622061
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Sethi S; Sethi N; Wadhwa V; Garud S; Brown A
Pancreas; 2014 Mar; 43(2):190-7. PubMed ID: 24518496
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of rectal indomethacin and sublingual nitrates to prevent post-ERCP pancreatitis.
Sotoudehmanesh R; Eloubeidi MA; Asgari AA; Farsinejad M; Khatibian M
Am J Gastroenterol; 2014 Jun; 109(6):903-9. PubMed ID: 24513806
[TBL] [Abstract][Full Text] [Related]
19. Covered self-expandable metal stents for pancreatic duct stricture: a systematic review and meta-analysis.
Tringali A; Costa D; Rota M; Adler DG; Costamagna G
Endosc Int Open; 2022 Sep; 10(9):E1311-E1321. PubMed ID: 36118636
[No Abstract] [Full Text] [Related]
20. Optimal timing of rectal diclofenac in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Sperna Weiland CJ; Smeets XJNM; Verdonk RC; Poen AC; Bhalla A; Venneman NG; Kievit W; Timmerhuis HC; Umans DS; van Hooft JE; Besselink MG; van Santvoort HC; Fockens P; Bruno MJ; Drenth JPH; van Geenen EJM;
Endosc Int Open; 2022 Mar; 10(3):E246-E253. PubMed ID: 35295242
[No Abstract] [Full Text] [Related]
[Next] [New Search]
